| Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function D Keszthelyi, FJ Troost, AAM Masclee Neurogastroenterology & Motility 21 (12), 1239-1249, 2009 | 311 | 2009 |
| Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome A Vich Vila, F Imhann, V Collij, SA Jankipersadsing, T Gurry, Z Mujagic, ... Science translational medicine 10 (472), eaap8914, 2018 | 234 | 2018 |
| Leaky gut and diabetes mellitus: what is the link? S De Kort, D Keszthelyi, AAM Masclee Obesity Reviews 12 (6), 449-458, 2011 | 232 | 2011 |
| Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome D Keszthelyi, FJ Troost, AA Masclee American Journal of Physiology-Gastrointestinal and Liver Physiology 303 (2 …, 2012 | 151 | 2012 |
| Large-scale association analyses identify host factors influencing human gut microbiome composition A Kurilshikov, C Medina-Gomez, R Bacigalupe, D Radjabzadeh, J Wang, ... Nature genetics 53 (2), 156-165, 2021 | 126 | 2021 |
| Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case–control study D Keszthelyi, SV Jansen, GA Schouten, S De Kort, B Scholtes, L Engels, ... Alimentary pharmacology & therapeutics 32 (9), 1124-1128, 2010 | 119 | 2010 |
| Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to … Z Mujagic, S Ludidi, D Keszthelyi, MAM Hesselink, JW Kruimel, ... Alimentary pharmacology & therapeutics 40 (3), 288-297, 2014 | 101 | 2014 |
| Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice Z Helyes, E Pintér, K Sándor, K Elekes, Á Bánvölgyi, D Keszthelyi, ... Proceedings of the National Academy of Sciences 106 (31), 13088-13093, 2009 | 96 | 2009 |
| Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff S Ludidi, JM Conchillo, D Keszthelyi, M Van Avesaat, JW Kruimel, ... Neurogastroenterology & Motility 24 (8), 729-e346, 2012 | 86 | 2012 |
| Rome III vs Rome IV criteria for irritable bowel syndrome: a comparison of clinical characteristics in a large cohort study L Vork, ZZRM Weerts, Z Mujagic, JW Kruimel, MAM Hesselink, JWM Muris, ... Neurogastroenterology & Motility 30 (2), e13189, 2018 | 73 | 2018 |
| Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach E Elamin, A Masclee, F Troost, HJ Pieters, D Keszthelyi, K Aleksa, ... PloS one 9 (9), e107421, 2014 | 68 | 2014 |
| Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review C Stillhart, K Vučićević, P Augustijns, AW Basit, H Batchelor, TR Flanagan, ... European Journal of Pharmaceutical Sciences 147, 105280, 2020 | 67 | 2020 |
| Effects of the somatostatin receptor subtype 4 selective agonist J‐2156 on sensory neuropeptide release and inflammatory reactions in rodents Z Helyes, E Pintér, J Németh, K Sándor, K Elekes, A Szabo, G Pozsgai, ... British journal of pharmacology 149 (4), 405-415, 2006 | 65 | 2006 |
| Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome ZZRM Weerts, AAM Masclee, BJM Witteman, CHM Clemens, B Winkens, ... Gastroenterology 158 (1), 123-136, 2020 | 64 | 2020 |
| Markers for visceral hypersensitivity in patients with irritable bowel syndrome S Ludidi, Z Mujagic, D Jonkers, D Keszthelyi, M Hesselink, J Kruimel, ... Neurogastroenterology & Motility 26 (8), 1104-1111, 2014 | 59 | 2014 |
| Gastrointestinal disorders in joint hypermobility syndrome/Ehlers‐Danlos syndrome hypermobility type: A review for the gastroenterologist AB Beckers, D Keszthelyi, A Fikree, L Vork, A Masclee, AD Farmer, Q Aziz Neurogastroenterology & Motility 29 (8), e13013, 2017 | 58 | 2017 |
| Incidence of microscopic colitis in the Netherlands. A nationwide population-based study from 2000 to 2012 BPM Verhaegh, DMAE Jonkers, A Driessen, MP Zeegers, D Keszthelyi, ... Digestive and liver disease 47 (1), 30-36, 2015 | 58 | 2015 |
| Alterations in serotonin metabolism in the irritable bowel syndrome AY Thijssen, Z Mujagic, D Jonkers, S Ludidi, D Keszthelyi, MA Hesselink, ... Alimentary Pharmacology & Therapeutics 43 (2), 272-282, 2016 | 57 | 2016 |
| Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review Z Vinarov, M Abdallah, JAG Agundez, K Allegaert, AW Basit, ... European Journal of Pharmaceutical Sciences 162, 105812, 2021 | 56 | 2021 |
| Revisiting concepts of visceral nociception in irritable bowel syndrome D Keszthelyi, FJ Troost, M Simrén, S Ludidi, JW Kruimel, JM Conchillo, ... European journal of pain 16 (10), 1444-1454, 2012 | 55 | 2012 |
Zsuzsanna HelyesPTE, ÁOK, Farmakológiai és Farmakoterápiai IntézetVerified email at szkk.pte.hu
